Premium
The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia
Author(s) -
Stoessl A. Jon,
Polanski Elizabeth,
Frydryszak Hanna
Publication year - 1993
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870080405
Subject(s) - tardive dyskinesia , opiate , (+) naloxone , antagonist , dyskinesia , medicine , pharmacology , anesthesia , schizophrenia (object oriented programming) , psychiatry , receptor , disease , parkinson's disease
The effects of both opiate agonists and the opiate antagonist naloxone were examined in a rodent model of tardive dyskinesia (TD). Chronic (˜20 weeks) administration of fluphenazine resulted in the emergence of vacuous chewing mouth movements (VCMs), a response which may be a useful model for this disorder. Fluphenazine‐induced VCMs were not affected by a variety of selective opiate agonists administered intracerebroventricularly, but were potently suppressed by subcutaneous administration of the opiate antagonist naloxone. These findings suggest that increased opiate transmission may contribute to the pathogenesis of TD. Further investigation of the role of opiate antagonists in treating this disorder are warranted.